Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763579 | 0.81 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL15069910 | 0.77 | MAPK14 (0.51) | KDM4EMAPT | |
| SCHEMBL11469111 | 0.76 | GAA (0.39) | SMN1; SMN2KDM4E | |
| SCHEMBL3774089 | 0.76 | SMN1; SMN2 (0.70) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL6731657 | 0.75 | — | — | |
| SCHEMBL29816548 | 0.75 | KDM4E (0.37) | SMN1; SMN2KMT2AKDM4EHTTL3MBTL1 | |
| SCHEMBL48934 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL13440741 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL2631528 | 0.73 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL3626130 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | claimed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | claimed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | claimed |
| US-12410161-B2 | Tetrahydrobenzo-quinoline sulfonamides derivative compounds | UCB Biopharma SRL (BE) | 2025-09-09 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | disclosed |
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| US-20230051300-A1 | TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS | UCB Biopharma SRL (BE) | 2023-02-16 | — | — | US | disclosed |
| EP-4081295-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| CN-1780832-A | 5-phenylthiazole derivatives and their use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2006-05-31 | — | — | CN | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
| US-4234594-A | Pyrazolyl amino imidazolines as antihypertensive agents | ABBOTT LABORATORIES (US) | 1980-11-18 | — | — | US | disclosed |
| US-4226773-A | Pyrazolyl amino imidazolines as diuretic agents | ABBOTT LABORATORIES (US) | 1980-10-07 | — | — | US | disclosed |
| US-4171367-A | ANTIINFLAMMATORY | ABBOTT LABORATORIES (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051300-A1 | TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS | HRH4, FCER2, HRH2 | SMN1; SMN2 4543/4885MEN1 4095/4885KMT2A 1231/4885 |
| US-12410161-B2 | Tetrahydrobenzo-quinoline sulfonamides derivative compounds | HRH4, FCER2, HRH2 | SMN1; SMN2 4543/4885MEN1 4095/4885KMT2A 1231/4885 |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | FCER2, FCGR2A, FCGR1A | SMN1; SMN2 4793/4885MEN1 4780/4885KMT2A 2467/4885 |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | SMN1; SMN2 3200/4885MEN1 1758/4885KMT2A 2160/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | SMN1; SMN2 4377/4885MEN1 2963/4885KMT2A 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.